Could not find much after drilling down through a few AR's I'm sure some of the Bloodhounds like stokdog, ecoool2, OP,WB777, The Yankee, the list goes on would be able to delve deeper and come up with some answers.
Under the purchase agreement milestone payments of a max of $40m US are due for use of Remestemcel-L in the treatment of aGVHD & Chrohn's disease and varying earnout amounts as a percentage of annual net sales for acquired products ranging from low single digit to 10% for annual sales in excess of $750m, so I guess if that sales target was achieved in one year then a payment of $75m +, but is this $750m sales figure just for Remestemcel-L or sales from all acquired products combined?
I know Osiris had two advanced products in Prochymel (Remestemcel-L) & Chondrogen and the company being founded by the Father of MSC's Arnold Caplan would have a bundle more in the vault at various stages of development.
Does the agreement cover the use of Remestemcel-L for other diseases such as ARDS?
I have not found any record of milestone payments to date.
Go to it hounds!
Cheers BK14
- Forums
- ASX - By Stock
- MSB
- 2 Thumbs Up for Mesoblast
2 Thumbs Up for Mesoblast, page-68
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
MSB (ASX) Chart |